Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Pfizer Inc. commenced its tender offer to acquire all outstanding shares of Warner-Lambert Company common stock.
Pfizer agreed to buy Warner-Lambert for about $91.5 billion in stock and assumed debt, ending a three-month hostile takeover battle and creating the world…
FTC Order Clears Way for $90 Billion Merger of Pfizer Inc. and Warner-Lambert Company.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Pfizer acquired Warner-Lambert in a $90 billion all-stock merger, ending a hostile takeover battle that began in November 1999. The deal gave Pfizer full ownership of Lipitor (atorvastatin), then the world's best-selling drug, along with Warner-Lambert's Parke-Davis pharmaceutical and consumer health portfolios.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Warner-Lambert Company (this deal) | 2000 | $90.0B | 83 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
| Pfizer Inc. / Seagen Inc. | 2023 | $43.0B | 77 |
← Browse all deals · How we score deals
More: 2000 deals · Pfizer Inc. deals · Cardiovascular deals